Fabrizio Tabbo

8PUBLICATIONS
124CO-AUTHORS
Molecular targetsCancer cell biologyCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 27, 2025
Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Oct 09, 2024
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors.

Ferdinandos Skoulidis, Haniel A Araujo, Minh Truong Do

|Jul 27, 2024
Clinical and Molecular Traits of a Novel SPECC1L-ALK Fusion in a Patient with Advanced Non-Small Cell Lung Cancer.

Antonella Centonza, Tommaso Mazza, Domenico Trombetta

|Jun 28, 2023
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma.

Cristina Mastini, Marco Campisi, Enrico Patrucco

|Jun 07, 2023
Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Dario P Anobile, Iris C Salaroglio, Fabrizio Tabbò

|Sep 27, 2022
Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells.

Ramona Rotolo, Valeria Leuci, Chiara Donini

Pageof 2